Form 4: Rocket Pharma Director Peter Fong Receives RSU Grant

Rocket Pharmaceuticals Director Peter Fong was granted 53,333 restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Peter Fong, a Director of Rocket Pharmaceuticals, Inc. (RCKT), was granted a total of 53,333 Restricted Stock Units (RSUs).
• The first grant consisted of 23,333 RSUs, which will vest in full on September 24, 2026.
• The second grant consisted of 30,000 RSUs, which will vest in equal monthly installments over a three-year period following September 23, 2025.
• These RSUs convert to common stock on a one-for-one basis.
• The transactions occurred on September 24, 2025, with a reported acquisition price of $0 per RSU, typical for grants.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is generally a positive signal for aligning interests but does not indicate extraordinary company performance or news.

Positives

• The grant of Restricted Stock Units to a director aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.
• The vesting schedules encourage continued commitment and retention of key board members.

Industry Context

The grant of Restricted Stock Units (RSUs) to directors is a standard practice in the biotechnology and pharmaceutical industry, serving as a common form of equity-based compensation to attract, retain, and incentivize experienced board members. This practice helps align the interests of directors with the long-term performance and strategic goals of the company.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common form of executive compensation in the biotechnology and pharmaceutical industry, aligning management interests with shareholder value.
• Specific comparable company compensation packages are not detailed in this filing, which focuses solely on the individual transaction.

Related Party Transactions

• Grant of 53,333 Restricted Stock Units to Director Peter Fong as part of his compensation.

Stakeholder Impact

• Shareholders: The RSU grants align the director's financial interests with long-term shareholder value, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Vesting of 23,333 RSUs in full on September 24, 2026.
• Monthly vesting of 30,000 RSUs over a three-year period starting September 23, 2025.

Key Dates

Keywords

ROCKET PHARMACEUTICALS, RCKT, Peter Fong, Director, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Compensation